Analysts’ Weekly Ratings Updates for Climb Bio (CLYM)

Several analysts have recently updated their ratings and price targets for Climb Bio (NASDAQ: CLYM):

• 3/10/2026 – Climb Bio is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating on the stock.
• 3/10/2026 – Climb Bio had its price target raised by HC Wainwright from $11.00 to $15.00. They now have a “buy” rating on the stock.
• 3/6/2026 – Climb Bio had its price target raised by Robert W. Baird from $9.00 to $12.00. They now have an “outperform” rating on the stock.
• 3/5/2026 – Climb Bio is now covered by Wedbush. They set an “outperform” rating and a $12.00 price target on the stock.
• 2/13/2026 – Climb Bio is now covered by Piper Sandler. They set an “overweight” rating on the stock.
• 1/21/2026 – Climb Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Climb Bio

In related news, Director Ra Capital Management, L.P. bought 101,462 shares of Climb Bio stock in a transaction on Friday, December 12th. The shares were purchased at an average price of $2.86 per share, for a total transaction of $290,181.32. Following the completion of the acquisition, the director owned 3,396,318 shares in the company, valued at approximately $9,713,469.48. This represents a 3.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.80% of the company’s stock.

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.